(EHAB) Enhabit - Overview

Sector: Healthcare | Industry: Medical Care Facilities | Exchange: NYSE (USA) | Market Cap: 693m USD | Total Return: 59.1% in 12m

Stock Home Health, Hospice, Therapy, Chronic Care
Total Rating 53
Safety 64
Buy Signal 0.33
Medical Care Facilities -10.5
Health Care Services +2.5
Market Cap: 693m
Avg Trading Vol: 17.8M USD
ATR: 0.98%
Peers RS (IBD): 95.0
Risk 5d forecast
Volatility48.4%
Rel. Tail Risk-19.0%
Reward TTM
Sharpe Ratio1.11
Alpha44.48
Character TTM
Beta1.016
Beta Downside1.637
Drawdowns 3y
Max DD54.82%
CAGR/Max DD0.04
EPS (Earnings per Share) EPS (Earnings per Share) of EHAB over the last years for every Quarter: "2021-03": null, "2021-06": null, "2021-09": null, "2021-12": null, "2022-03": 0.5711, "2022-06": 0.47, "2022-09": 0.19, "2022-12": 0.32, "2023-03": 0.09, "2023-06": 0.04, "2023-09": 0.03, "2023-12": 0.06, "2024-03": 0.07, "2024-06": 0.07, "2024-09": 0.03, "2024-12": 0.04, "2025-03": 0.1, "2025-06": 0.1, "2025-09": 0.17, "2025-12": 0.14, "2026-03": 0,
EPS CAGR: -66.40%
EPS Trend: -50.7%
Last SUE: -4.00
Qual. Beats: 0
Revenue Revenue of EHAB over the last years for every Quarter: 2021-03: 270.5, 2021-06: 286.1, 2021-09: 273.9, 2021-12: 276.1, 2022-03: 274.3, 2022-06: 268, 2022-09: 265.7, 2022-12: 275.1, 2023-03: 265.1, 2023-06: 262.3, 2023-09: 258.3, 2023-12: 260.6, 2024-03: 262.4, 2024-06: 260.6, 2024-09: 253.6, 2024-12: 258.2, 2025-03: 259.9, 2025-06: 266.1, 2025-09: 263.6, 2025-12: 270.4, 2026-03: null,
Rev. CAGR: -0.38%
Rev. Trend: -39.4%
Last SUE: -0.04
Qual. Beats: 0
Description: EHAB Enhabit

Enhabit, Inc. (NYSE: EHAB) operates a nationwide network of home-health and hospice providers, delivering services such as skilled nursing, wound care, infusion therapy, and rehabilitative therapies, as well as comprehensive end-of-life support that includes pain management, counseling, and spiritual care.

In its latest quarter (Q4 2023), Enhabit reported revenue of $162 million, a 7% year-over-year increase driven by a 5% rise in patient admissions and higher case-mix intensity; adjusted EBITDA margin expanded to 6.2%, up from 5.5% in the prior year. The company’s home-health census grew to 8,300 active patients, reflecting robust demand for chronic-disease management.

Key sector catalysts include the aging U.S. population-U.S. Census data projects that adults 65+ will comprise 21% of the population by 2030-and ongoing Medicare policy shifts that favor home-based care over inpatient settings, boosting reimbursement rates for qualified home-health services.

For a deeper dive, you might explore ValueRay’s detailed analysis of EHAB.

Headlines to Watch Out For
  • Medicare reimbursement rates for home health and hospice services impact revenue
  • Labor costs for skilled nurses and therapists pressure margins
  • Regulatory changes in healthcare policy create operational uncertainty
  • Patient volume and referrals drive service demand
Piotroski VR‑10 (Strict) 5.0
Net Income: -4.60m TTM > 0 and > 6% of Revenue
FCF/TA: 0.06 > 0.02 and ΔFCF/TA 1.77 > 1.0
NWC/Revenue: 7.48% < 20% (prev 6.43%; Δ 1.05% < -1%)
CFO/TA 0.06 > 3% & CFO 70.7m > Net Income -4.60m
Net Debt (456.4m) to EBITDA (86.3m): 5.29 < 3
Current Ratio: 1.63 > 1.5 & < 3
Outstanding Shares: last quarter (50.7m) vs 12m ago 1.00% < -2%
Gross Margin: 46.92% > 18% (prev 0.47%; Δ 4.64k% > 0.5%)
Asset Turnover: 88.59% > 50% (prev 84.40%; Δ 4.18% > 0%)
Interest Coverage Ratio: 1.88 > 6 (EBITDA TTM 86.3m / Interest Expense TTM 34.0m)
Altman Z'' 1.23
A: 0.07 (Total Current Assets 205.6m - Total Current Liabilities 126.3m) / Total Assets 1.17b
B: 0.08 (Retained Earnings 93.7m / Total Assets 1.17b)
C: 0.05 (EBIT TTM 63.8m / Avg Total Assets 1.20b)
D: 0.16 (Book Value of Equity 94.2m / Total Liabilities 603.0m)
Altman-Z'' Score: 1.23 = BB
Beneish M -3.13
DSRI: 0.94 (Receivables 144.0m/149.2m, Revenue 1.06b/1.03b)
GMI: 1.01 (GM 46.92% / 47.22%)
AQI: 0.98 (AQ_t 0.77 / AQ_t-1 0.79)
SGI: 1.02 (Revenue 1.06b / 1.03b)
TATA: -0.06 (NI -4.60m - CFO 70.7m) / TA 1.17b)
Beneish M-Score: -3.13 (Cap -4..+1) = AA
What is the price of EHAB shares? As of April 03, 2026, the stock is trading at USD 14.09 with a total of 1,317,056 shares traded.
Over the past week, the price has changed by +2.49%, over one month by +3.09%, over three months by +54.02% and over the past year by +59.09%.
Is EHAB a buy, sell or hold? Enhabit has received a consensus analysts rating of 3.40. Therefor, it is recommend to hold EHAB.
  • StrongBuy: 1
  • Buy: 0
  • Hold: 4
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the EHAB price?
Wallstreet Target Price 13.8 -2.1%
Analysts Target Price 13.8 -2.1%
EHAB Fundamental Data Overview as of 31 March 2026
P/E Forward = 23.4742
P/S = 0.6537
P/B = 1.2937
Revenue TTM = 1.06b USD
EBIT TTM = 63.8m USD
EBITDA TTM = 86.3m USD
Long Term Debt = 426.0m USD (from longTermDebt, last quarter)
Short Term Debt = 34.9m USD (from shortTermDebt, last quarter)
Debt = 500.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 456.4m USD (from netDebt column, last quarter)
Enterprise Value = 1.15b USD (692.9m + Debt 500.0m - CCE 43.6m)
Interest Coverage Ratio = 1.88 (Ebit TTM 63.8m / Interest Expense TTM 34.0m)
EV/FCF = 17.47x (Enterprise Value 1.15b / FCF TTM 65.8m)
FCF Yield = 5.73% (FCF TTM 65.8m / Enterprise Value 1.15b)
FCF Margin = 6.21% (FCF TTM 65.8m / Revenue TTM 1.06b)
Net Margin = -0.43% (Net Income TTM -4.60m / Revenue TTM 1.06b)
Gross Margin = 46.92% ((Revenue TTM 1.06b - Cost of Revenue TTM 562.7m) / Revenue TTM)
Gross Margin QoQ = 42.49% (prev 48.48%)
Tobins Q-Ratio = 0.98 (Enterprise Value 1.15b / Total Assets 1.17b)
Interest Expense / Debt = 1.52% (Interest Expense 7.60m / Debt 500.0m)
Taxrate = 21.0% (US default 21%)
NOPAT = 50.4m (EBIT 63.8m * (1 - 21.00%))
Current Ratio = 1.63 (Total Current Assets 205.6m / Total Current Liabilities 126.3m)
Debt / Equity = 0.94 (Debt 500.0m / totalStockholderEquity, last quarter 534.0m)
Debt / EBITDA = 5.29 (Net Debt 456.4m / EBITDA 86.3m)
Debt / FCF = 6.94 (Net Debt 456.4m / FCF TTM 65.8m)
Total Stockholder Equity = 549.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.38% (Net Income -4.60m / Total Assets 1.17b)
RoE = -0.84% (Net Income TTM -4.60m / Total Stockholder Equity 549.1m)
RoCE = 6.54% (EBIT 63.8m / Capital Employed (Equity 549.1m + L.T.Debt 426.0m))
RoIC = 4.94% (NOPAT 50.4m / Invested Capital 1.02b)
WACC = 6.05% (E(692.9m)/V(1.19b) * Re(9.55%) + D(500.0m)/V(1.19b) * Rd(1.52%) * (1-Tc(0.21)))
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.70%
[DCF] Terminal Value 88.22% ; FCFF base≈58.4m ; Y1≈71.8m ; Y5≈121.4m
[DCF] Fair Price = 59.27 (EV 3.46b - Net Debt 456.4m = Equity 3.01b / Shares 50.7m; r=6.05% [WACC]; 5y FCF grow 24.46% → 3.0% )
EPS Correlation: -50.71 | EPS CAGR: -66.40% | SUE: -4.0 | # QB: 0
Revenue Correlation: -39.40 | Revenue CAGR: -0.38% | SUE: -0.04 | # QB: 0
EPS next Quarter (2026-06-30): EPS=0.16 | Chg7d=+0.032 | Chg30d=+0.032 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=0.60 | Chg7d=-0.002 | Chg30d=-0.002 | Revisions Net=+0 | Growth EPS=+13.8% | Growth Revenue=+4.4%
EPS next Year (2027-12-31): EPS=0.62 | Chg7d=-0.016 | Chg30d=-0.016 | Revisions Net=-1 | Growth EPS=+3.0% | Growth Revenue=+5.0%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle